Medical Cannabis and Behavior
RecruitingNot applicableNCT06808048
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This study will assess cognition, neural function, and drug exposure in chronic pain patients who have been prescribed medical cannabis and will differentiate outcomes based on use of specific CBD-dominant versus THC-dominant treatment products. This longitudinal study will recruit medical cannabis users from local dispensaries. Each participant will complete a baseline assessment prior to the start of medical cannabis use, monthly phone calls to assess treatment adherence, and a four-month follow- up assessment. The aims of this project are: Aim 1. To assess impacts of medical cannabis compounds on executive functions, learning and memory in adults to determine whether cognitive impairments are evident after the onset of cannabis use; Aim 2. To assess the impacts of medical cannabis compounds on white matter microstructure, functional brain activity and functional connectivity; Aim 3. To differentiate change over four months in these outcomes as a function of (a) age and (b) pre-to-post-treatment changes in blood levels of cannabinoid compounds.
Study details
- Official title
- Neurobehavioral Impacts of Medical Cannabis Use: An Observational Study
- Conditions
- Chronic Pain Patients
- Medical Cannabis Users
- Interventions
- Behavioral: Cognitive testing
- Behavioral: Task-based fMRI measure of face-name and verbal learning
- Sponsor
- University of Minnesota
- Collaborators
- National Institute on Drug Abuse (NIDA)
- Start date
- 2025-06-18
- Primary completion
- 2029-07-15
- Sex
- All
- Age range
- from 30 Years to 75 Years
- Results posted
- No results posted in this snapshot
- Countries
- United States
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Medical cannabis users (n=120) will be required to 1. Be ages 30-75; 2. Be qualified for a medical cannabis prescription based only on a diagnosis of chronic pain; note that individuals can, in theory, utilize medical cannabis for more than one qualifying condition. People with orthopedic pain will be prioritized. 3. Have normal or corrected-to-normal vision and hearing; 4. Be free of current and past DSM-V-defined substance use disorders; have \< 5 lifetime recreational uses of illicit drugs. 5. Have limited daily exposure to nicotine (e.g., no daily smokers/vapers; use of nicotine products fewer than 5 occasions weekly); 6. Willing to abstain from alcohol, nicotine, and other (non-treatment) drugs for 24 hours prior to study. Abstinence will be verified by breathalyzer and urine drug screening; must not test positive on breathalyzer and urine drug screenings for any nonprescribed psychoactive substance or for cannabis (at baseline); 7. Must be right handed as assessed by the Edinburgh Handedness Inventory; 8. No history of daily cannabis use; limited cannabis product use (recreational or therapeutic) within the past three months; 9. Able to schedule and complete a multi-hour single session protocol; 10. Have sufficient manual mobility to be able to complete computerized neurocognitive assessments; 11. Able to communicate with the researchers by phone during the four month pre-post assessment interval Pain patients who are not using medical cannabis (n=60) will be required to: 1. Be ages 30-75; 2. Suffer from a chronic pain condition that could qualify them for medical cannabis; People with orthopedic pain will be prioritized. 3. Have normal or corrected-to-normal vision and hearing; 4. Be free of current and past DSM-V-defined substance use disorders; have \< 5 lifetime recreational uses of illicit drugs. 5. Have limited daily exposure to nicotine (e.g., no daily smokers/vapers; use of nicotine products fewer than 5 occasions weekly); 6. Willing to abstain from alcohol, nicotine, and other (non-treatment) drugs for 24 hours prior to study. Abstinence will be verified by breathalyzer and urine drug screening; must not test positive on breathalyzer and urine drug screenings for any non- prescribed psychoactive substance or for cannabis (at baseline); 7. Must be right handed as assessed by the Edinburgh Handedness Inventory; 8. No history of daily cannabis use; cannabis use within the past three months limited to a few times. 9. Able to s…
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT06808048